Is there a Bangladeshi generic version of Entrectinib?

Entrectinib (Entrectinib) is a multi-target oral targeted therapy drug, mainly used to treat tumors positive for specific gene fusions.

Enrectinib is a multi-target inhibitor that can inhibit the activity of multiple kinases at the same time, including ROS1, NTRK and ALK, etc. It inhibits the growth and spread of tumor cells by interfering with the signaling pathways of these kinases.

There is currently no Bangladeshi generic version of Entrectinib on the market. Entrectinib has been launched in China, but due to its short time on the market, it has not yet been included in the medical insurance catalog. Since it has just been launched, it is difficult to purchase domestically and the price is very high. For specific prices, please consult the hospital pharmacy at that time. There are original drugs and generic drugs abroad. The original drugs abroad are mainly European versions of original drugs. The price is about 45,000 yuan. The price is relatively high and may be unaffordable for ordinary families. Generic drugs are mainly Lao generic drugs, with prices ranging from 4,000 to 8,000yuan, which are much cheaper than original drugs, and the ingredients of original drugs and generic drugs are basically the same.

Enrectinib has shown significant efficacy in clinical trials, particularly in tumors positive for specific gene fusions. Clinical trial data indicate that entrectinib can induce tumor shrinkage or stabilization in patients with these gene fusion-positive tumors. Entrectinib has shown a high overall effectiveness against ROS1 fusion-positive NSCLC and NTRK NTRK gene fusion-positive solid tumors.

The use of tratinib may cause some side effects, including fatigue, nausea, vomiting, diarrhea, loss of appetite, etc. Patients should pay close attention to their condition while using the drug and communicate with their doctor when necessary.

The use of entrectinib should be done under the guidance of a doctor. Doctors will develop the most appropriate treatment plan based on comprehensive factors such as the patient's genotype, tumor characteristics, and health status. Patients and doctors should discuss the benefits, risks, and possible side effects of treatment together to ensure that the patient gets the best possible outcome.